Peptides Bound to Commonly Used Orthopaedic and Dental Biomaterials:In Vitro and in Vivo Effect on Osteogenesis.

1992年，骨科行业安装了大约30万个假肢装置，人工髋关节，膝关节，使该行业的全球市场达到21亿美元，预计市场增长率超过每年10%。1994年至1995年，在新南威尔士州手术植入了5，717例人工髋关节和4，593例膝关节，其中14%的髋关节和9.5%的膝关节进行了翻修。相当多的卫生资金分配给国家的关节置换，虽然成功，结果是有限的。重要的是，除了成本，患者的发病率很高。这些假体置换长期失败的主要原因是无菌性松动，这是骨-器械界面骨丢失的结果。开发更有效的植入材料的新方法最终将对这些患者的活动性和生活质量做出重大贡献。为了改善骨科植入物与骨骼的互锁，人们已经付出了相当大的努力来改变骨科植入物的表面特性。我们是第一个证明使用选定离子对生物材料进行表面化学修饰可以增强骨形成的人。该提案旨在对常用骨科和牙科材料的表面进行化学改性，以改善新器械的生物相容性和现有假体的表面涂层。此外，该应用将建立在体外数据的基础上，这些数据显示特定的肽特异性结合成骨细胞，因此有可能在假体上提供有助于骨形成的表面。到目前为止，我们已经将这些肽偶联到金属表面，并将继续研究成骨细胞表型和随后的骨生成。这些新型生物相容性表面的开发预计将降低患者发病率，并节省大量医疗费用。

In 1992, the orthopaedics industry fitted some 300,000 prosthetic devices, artificial hips, knees, giving this industry a global market of $2.1 billion with a projected market growth exceeding 10% per annum. In (1994-5) 5,717 prosthetic hips and 4,593 knees were surgically implanted in NSW of which 14% of hips and 9.5% of knees were revisions. Considerable health funding is allocated to joint replacement for the nation, although successful, outcomes are finite. Importantly, and aside from costs, patients morbidity is high. The major cause of long-term failure of these prosthetic replacements is aseptic loosening, the result of bone loss at the bone-device interface. Novel approaches to development of more efficient implant materials would ultimately lead to major contributions to the mobility and and quality of life for these patients. Considerable effort has been devoted to alter surface characteristics of orthopaedic implants to improve the interlocking of device and skeleton. We were the first to demonstrate that surface chemical modification of biomaterials using selected ions resulted in an enhanced bone formation. This proposal is aimed at chemically modifying the surfaces of commonly used orthopaedic and dental materials, to improve the biocompatibility of new devices and the surface coatings for existing prostheses. Furthermore, this application will build on the in vitro data showing that particular peptides specifically bind osteoblasts and therefore have the potential to provide a surface on a prosthesis that is conducive to bone formation. To date, we have coupled these peptides to metallic surfaces and will proceed to study the osteoblastic phenotype and subsequent osteogenesis. Development of these novel biocompatible surfaces is anticipated to reduce patient morbidity and result in significant health care savings.